Literature DB >> 17928506

Importance of donor- and recipient-derived selectins in cardiac allograft rejection.

Atsushi Izawa1, Takuya Ueno, Mollie Jurewicz, Toshiro Ito, Katsunori Tanaka, Masafumi Takahashi, Uichi Ikeda, Olga Sobolev, Paolo Fiorina, Rex Neal Smith, Richard O Hynes, Reza Abdi.   

Abstract

The selectins expressed on activated endothelial cells (E- and P-selectin), leukocytes (L-selectin), and platelets (P-selectin) play crucial roles in the rolling and tethering of leukocytes. We explored the importance of donor and recipient selectins in acute and chronic cardiac allograft rejection using mice deficient in all three selectins (ELP-/-). In BALB/c recipients, survival of fully allomismatched hearts from ELP-/- C57BL/6 donors was almost double that of wild-type grafts. In ELP-/- cardiac allografts, mononuclear cell infiltration and vasculitis of intramyocardial coronary arteries were significantly reduced. Interestingly, ELP-/- grafts were rejected similarly in both the presence and the absence of recipient selectins, and both wild-type and ELP-/- recipients promptly rejected wild-type hearts. Alternative adhesive molecules such as alpha4beta7 integrin may compensate for the lack of selectins and may mediate rejection in ELP-/- recipients. Chronic rejection was evaluated in a major histocompatibility complex (MHC) class II mismatch model using C57BL/6.C-H2(bm12) mice. While lack of selectins in recipients did not offer protection against chronic rejection, luminal stenosis of coronary arteries in ELP-/- grafts was markedly diminished. In conclusion, donor-derived selectins contribute to the development of both acute and chronic cardiac allograft rejection, and targeting donor selectins may open novel therapeutic approaches in clinical transplantation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17928506     DOI: 10.1681/ASN.2006111261

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  9 in total

1.  Blockade of p-selectin is sufficient to reduce MHC I antibody-elicited monocyte recruitment in vitro and in vivo.

Authors:  N M Valenzuela; L Hong; X-Da Shen; F Gao; S H Young; E Rozengurt; J W Kupiec-Weglinski; M C Fishbein; E F Reed
Journal:  Am J Transplant       Date:  2012-12-27       Impact factor: 8.086

2.  Testing the Efficacy of Contrast-Enhanced Ultrasound in Detecting Transplant Rejection Using a Murine Model of Heart Transplantation.

Authors:  K Fischer; S Ohori; F C Meral; M Uehara; S Giannini; T Ichimura; R N Smith; F A Jolesz; I Guleria; Y Zhang; P J White; N J McDannold; K Hoffmeister; M M Givertz; R Abdi
Journal:  Am J Transplant       Date:  2017-02-01       Impact factor: 8.086

3.  Polylactide-cyclosporin A nanoparticles for targeted immunosuppression.

Authors:  Jamil Azzi; Li Tang; Robert Moore; Rong Tong; Najib El Haddad; Takurin Akiyoshi; Bechara Mfarrej; Sunmi Yang; Mollie Jurewicz; Takaharu Ichimura; Neal Lindeman; Jianjun Cheng; Reza Abdi
Journal:  FASEB J       Date:  2010-06-14       Impact factor: 5.191

4.  Impaired selectin-dependent leukocyte recruitment induces T-cell exhaustion and prevents chronic allograft vasculopathy and rejection.

Authors:  Bara Sarraj; Junsheng Ye; Ahmed Ibrahim Akl; Guodong Chen; Jiao-Jing Wang; Zheng Zhang; Farida Abadja; Michael Abecassis; Stephen D Miller; Geoffrey S Kansas; M Javeed Ansari
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

5.  Endothelial activation, lymphangiogenesis, and humoral rejection of kidney transplants.

Authors:  Sharon Phillips; Meghan Kapp; Deborah Crowe; Jorge Garces; Agnes B Fogo; Giovanna A Giannico
Journal:  Hum Pathol       Date:  2016-01-14       Impact factor: 3.466

6.  Immunosuppressive Activity of Size-Controlled PEG-PLGA Nanoparticles Containing Encapsulated Cyclosporine A.

Authors:  Li Tang; Jamil Azzi; Mincheol Kwon; Marwan Mounayar; Rong Tong; Qian Yin; Robert Moore; Nikolaos Skartsis; Timothy M Fan; Reza Abdi; Jianjun Cheng
Journal:  J Transplant       Date:  2012-03-29

Review 7.  Cardiac allograft vasculopathy: a donor or recipient induced pathology?

Authors:  Patricia van den Hoogen; Manon M H Huibers; Joost P G Sluijter; Roel A de Weger
Journal:  J Cardiovasc Transl Res       Date:  2015-02-05       Impact factor: 4.132

8.  Cardiac Graft Assessment in the Era of Machine Perfusion: Current and Future Biomarkers.

Authors:  Martina Bona; Rahel K Wyss; Maria Arnold; Natalia Méndez-Carmona; Maria N Sanz; Dominik Günsch; Lucio Barile; Thierry P Carrel; Sarah L Longnus
Journal:  J Am Heart Assoc       Date:  2021-01-30       Impact factor: 5.501

9.  Novel therapeutic and diagnostic management of heart transplant patients.

Authors:  Davide Margonato; Umberto Pensato; Francesca D'Addio; Laura Borgese; Luciano Potena; Paolo Fiorina
Journal:  Heart Lung Vessel       Date:  2015
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.